Messenger RNA COVID-19 vaccines greatly reduce risk of asymptomatic COVID-19 infection, spread to ot

vaccine
Credit: Pixabay/CC0 Public Domain

Ten days after receiving a second dose of a messenger RNA, or mRNA, vaccine for COVID-19, patients without COVID-19 symptoms are far less likely to test positive and unknowingly spread COVID-19, compared to patients who have not been vaccinated for COVID-19. The Pfizer-BioNTech and Moderna messenger RNA vaccines for COVID-19 are authorized for emergency use in the U.S.

With two doses of a RNA COVID-19 , people with no symptoms showed an 80% lower adjusted risk of testing positive for COVID-19 after their last dose. Those are the findings of a Mayo Clinic study of vaccinated patients. These finding appear in the journal Clinical Infectious Diseases.

The authors say these findings underscore the efficacy of messenger RNA vaccines for COVID-19 to significantly limit the spread of COVID-19 by people with no symptoms who may unknowingly spread the infection to others.

The researchers retrospectively looked at a cohort of 39,000 patients who underwent pre-procedural molecular for COVID-19. More than 48,000 tests were performed, including 3,000 screening tests on patients who had received at least one dose of a messenger RNA COVID-19 vaccine. These screening tests were part of routine COVID-19 testing prior to treatments not related to COVID-19, such as surgeries and other procedures. Patients in the vaccinated group had received at least one dose of a messenger RNA COVID-19 vaccine.

"We found that those patients without symptoms receiving at least one dose of the first authorized mRNA COVID-19 vaccine, Pfizer-BioNTech, 10 days or more prior to screening were 72% less likely to positive," says Aaron Tande, M.D., a Mayo Clinic infectious diseases specialist and co-first author of the paper. "Those receiving two doses were 73% less likely, compared to the unvaccinated group."

After adjusting for a range of factors, researchers found an 80% risk reduction of testing positive for COVID-19 among those with two doses of a messenger RNA COVID-19 vaccine.

The study was based on receiving screening tests between Dec. 17, 2020, and Feb. 8 at Mayo Clinic in Minnesota and Arizona and at Mayo Clinic Health System in Minnesota and Wisconsin.


Explore further

Follow the latest news on the coronavirus (COVID-19) outbreak

More information: Aaron J Tande et al. Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening, Clinical Infectious Diseases (2021). DOI: 10.1093/cid/ciab229
Journal information: Clinical Infectious Diseases

Provided by Mayo Clinic
Citation: Messenger RNA COVID-19 vaccines greatly reduce risk of asymptomatic COVID-19 infection, spread to ot (2021, March 11) retrieved 14 May 2021 from https://medicalxpress.com/news/2021-03-messenger-rna-covid-vaccines-greatly.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
19 shares

Feedback to editors

User comments